HRP20050679A2 - Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors - Google Patents
Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitorsInfo
- Publication number
- HRP20050679A2 HRP20050679A2 HR20050679A HRP20050679A HRP20050679A2 HR P20050679 A2 HRP20050679 A2 HR P20050679A2 HR 20050679 A HR20050679 A HR 20050679A HR P20050679 A HRP20050679 A HR P20050679A HR P20050679 A2 HRP20050679 A2 HR P20050679A2
- Authority
- HR
- Croatia
- Prior art keywords
- denotes
- nr5r6
- cycloalkyl
- alkyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Izum se odnosi na nove produkte koji imaju formulu (I), u kojoj: primjer označava 0 do 2, Radikal iR1 označavaju 0 ili NH; R2 i R3 označavaju vodik,alkil, alkenil, alkinil, cikloalkil, aril ili heteroaril, ili R2 i R3, zajedno s atomom ugljika na kojeg su vezani, tvore karbociklički ili heterociklički radikal, svi od navedenih radikala su po izboru supstituirani; A1 označava jednostruku vezu, alkil, alil ili propinil; Y i Y1 označavaju vodik, OCF3, S(O)nCF3, S(O)Alk, SO2CHF2, SO2CF2CF3, -O-CF2-CHF2, -O-CHF2, -O-CH2-CF3, SF5 i SO2NR5NR6, gdjesu R5 i R6 izabrani između vodika, alkil, alkenil, cikloalkil, cikloalkenil, heterocikloalkil, arili heteroaril, koji su po izboru supstituirani, ili R5 i R6 zajedno s N atomom na kojeg su vezani, tvore heterociklički radikal; A2 označava A1, CO i SO2; B2 označava heterociklički radikal koji je poizboru supstituiran s jednim ili više supstituenta koji su izabrani između mogućnosti od Y2; Y2 označava vodik, halogen, hidroksil, ciano, alkil, alkoksi, cikloalkil, heterocikloalkil, aril, heteroaril, -O-alkenil, -O-alkinil, -O-cikloalkil, S(O)n-alkil, - S(O)n-alkenil, - S(O)n-alkinil, - S(O)n-cikloalkil, -C00R13, NR5R6, CONR5R6, S(O)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, -NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, svi od navedenih radikala su po izboru supstituiran; i n označava cijeli broj između 0 i 2. Za uporabu kao medikamenata, ranije spomenuti produkti su u svim izomernim oblicima i soli od njih.The invention relates to novel products having the formula (I), in which: example denotes 0 to 2, Radical and R 1 denote 0 or NH; R 2 and R 3 denote hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl, or R 2 and R 3, together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic radical, all of which radicals are optionally substituted; A1 denotes a single bond, alkyl, allyl or propynyl; Y and Y1 denote hydrogen, OCF3, S (O) nCF3, S (O) Alk, SO2CHF2, SO2CF2CF3, -O-CF2-CHF2, -O-CHF2, -O-CH2-CF3, SF5 and SO2NR5NR6, where R5 and R 6 selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl heteroaryl, which are optionally substituted, or R 5 and R 6 together with the N atom to which they are attached form a heterocyclic radical; A2 denotes A1, CO and SO2; B2 denotes a heterocyclic radical optionally substituted with one or more substituents selected from the possibility of Y2; Y2 denotes hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-alkenyl, -O-alkynyl, -O-cycloalkyl, S (O) n-alkyl, - S (O) n-alkenyl, -S (O) n-alkynyl, -S (O) n-cycloalkyl, -C00R13, NR5R6, CONR5R6, S (O) n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13 , -NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, all of these radicals are optionally substituted; and n denotes an integer between 0 and 2. For use as medicaments, the aforementioned products are in all isomeric forms and salts thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0301098A FR2850652B1 (en) | 2003-01-31 | 2003-01-31 | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
| PCT/FR2004/000188 WO2004070050A2 (en) | 2003-01-31 | 2004-01-28 | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050679A2 true HRP20050679A2 (en) | 2006-12-31 |
Family
ID=32696243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050679A HRP20050679A2 (en) | 2003-01-31 | 2005-07-29 | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1599464B1 (en) |
| JP (1) | JP4604020B2 (en) |
| KR (1) | KR20050098286A (en) |
| CN (1) | CN1768054A (en) |
| AR (1) | AR042936A1 (en) |
| AT (1) | ATE482207T1 (en) |
| AU (1) | AU2004209319A1 (en) |
| BR (1) | BRPI0407091A (en) |
| CA (1) | CA2513631A1 (en) |
| DE (1) | DE602004029236D1 (en) |
| FR (1) | FR2850652B1 (en) |
| HR (1) | HRP20050679A2 (en) |
| MA (1) | MA27651A1 (en) |
| ME (1) | MEP22608A (en) |
| MX (1) | MXPA05007407A (en) |
| NO (1) | NO20054006L (en) |
| NZ (1) | NZ541270A (en) |
| PE (1) | PE20040808A1 (en) |
| PL (1) | PL377811A1 (en) |
| RS (1) | RS20050657A (en) |
| RU (1) | RU2341523C2 (en) |
| TW (1) | TW200505898A (en) |
| WO (1) | WO2004070050A2 (en) |
| ZA (1) | ZA200505934B (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077344A2 (en) | 2003-08-29 | 2005-08-25 | The Brigham And Women's Hospital, Inc. | Hydantoin derivatives as inhibitors of cellular necrosis |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| JP2007514442A (en) | 2003-12-19 | 2007-06-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Methods and materials for evaluating prostate cancer treatment |
| WO2005099693A2 (en) | 2004-02-24 | 2005-10-27 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
| EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| EP1621535A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| ES2535179T3 (en) | 2005-05-13 | 2015-05-06 | The Regents Of The University Of California | Diarylhydantoin compound as androgen receptor antagonists for cancer treatment |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| FR2896503B1 (en) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
| FR2896504B1 (en) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
| EP3835294A1 (en) | 2006-03-27 | 2021-06-16 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| JP2010512389A (en) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | Aspartyl protease inhibitor |
| JP5535925B2 (en) | 2007-10-26 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Diarylhydantoin compounds as androgen receptor modulators |
| US20120122889A1 (en) | 2008-12-23 | 2012-05-17 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
| SG10201501202TA (en) | 2010-02-16 | 2015-04-29 | Aragon Pharmaceuticals Inc | Androgen Receptor Modulators And Uses Thereof |
| EP2655428B1 (en) * | 2010-12-21 | 2022-09-14 | Cytec Technology Corp. | Microdispersions of hydroxamated polymers and methods of making and using them |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (en) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| GB201312492D0 (en) * | 2013-07-12 | 2013-08-28 | Syngenta Ltd | Herbicidal compounds |
| BR112016016289B1 (en) | 2014-01-14 | 2023-02-07 | Takeda Pharmaceutical Company Limited | HETEROARIS AND USES THEREOF |
| EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN107530350A (en) | 2014-12-11 | 2018-01-02 | 哈佛理事会 | Inhibitor of cellular necrosis and correlation technique |
| TWI726969B (en) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | Substituted thiohydantoin derivatives as androgen receptor antagonists |
| CN107619388A (en) * | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | Heterocyclic compound as FGFR inhibitor |
| EP4442317A2 (en) * | 2016-07-20 | 2024-10-09 | Novartis AG | Aminopyridine derivatives and their use as selective alk-2 inhibitors |
| SG11202003402QA (en) | 2017-10-16 | 2020-05-28 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| RU2763346C2 (en) * | 2017-10-31 | 2021-12-28 | Пелемед Ко., Лтд. | Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic mammary gland cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2329276A1 (en) * | 1975-10-29 | 1977-05-27 | Roussel Uclaf | NEW SUBSTITUTES IMIDAZOLIDINES, METHOD OF PREPARATION, APPLICATION AS A MEDICINAL PRODUCT AND COMPOSITIONS CONTAINING THEM |
| DE4228717A1 (en) * | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidine derivatives |
| DE19540027A1 (en) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituted imidazolidine-2,4-dione compounds as active pharmaceutical ingredients |
| DE69811867T2 (en) * | 1997-03-03 | 2003-11-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | SMALL MOLECULES APPLICABLE IN TREATING INFLAMMATORY DISEASES |
| DE19732928C2 (en) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Use of substituted imidazolidine-2,4-dione compounds as pain relievers |
| FR2796945B1 (en) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | NOVEL DERIVATIVES OF HYDANTOINS, THIOHYDANTOINS, PYRIMIDINEDIONES AND THIOXOPYRIMIDINONES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
| NZ522852A (en) * | 2000-05-31 | 2004-09-24 | Tanabe Seiyaku Co | Inhibitors of alpha L beta 2 mediated cell adhesion |
| PL374162A1 (en) * | 2002-05-16 | 2005-10-03 | Bayer Cropscience Gmbh | Pyridine carboxamide derivatives and their use as pesticides |
-
2003
- 2003-01-31 FR FR0301098A patent/FR2850652B1/en not_active Expired - Fee Related
-
2004
- 2004-01-22 PE PE2004000090A patent/PE20040808A1/en not_active Application Discontinuation
- 2004-01-27 AR ARP040100233A patent/AR042936A1/en unknown
- 2004-01-28 JP JP2006502123A patent/JP4604020B2/en not_active Expired - Fee Related
- 2004-01-28 CN CNA2004800088356A patent/CN1768054A/en active Pending
- 2004-01-28 ME MEP-226/08A patent/MEP22608A/en unknown
- 2004-01-28 RU RU2005127335/04A patent/RU2341523C2/en not_active IP Right Cessation
- 2004-01-28 AU AU2004209319A patent/AU2004209319A1/en not_active Abandoned
- 2004-01-28 WO PCT/FR2004/000188 patent/WO2004070050A2/en active Application Filing
- 2004-01-28 EP EP04705838A patent/EP1599464B1/en not_active Expired - Lifetime
- 2004-01-28 PL PL377811A patent/PL377811A1/en not_active Application Discontinuation
- 2004-01-28 AT AT04705838T patent/ATE482207T1/en not_active IP Right Cessation
- 2004-01-28 RS YUP-2005/0657A patent/RS20050657A/en unknown
- 2004-01-28 MX MXPA05007407A patent/MXPA05007407A/en active IP Right Grant
- 2004-01-28 BR BR0407091-7A patent/BRPI0407091A/en not_active IP Right Cessation
- 2004-01-28 CA CA002513631A patent/CA2513631A1/en not_active Abandoned
- 2004-01-28 DE DE602004029236T patent/DE602004029236D1/en not_active Expired - Lifetime
- 2004-01-28 NZ NZ541270A patent/NZ541270A/en unknown
- 2004-01-28 KR KR1020057014096A patent/KR20050098286A/en not_active Application Discontinuation
- 2004-01-30 TW TW093102064A patent/TW200505898A/en unknown
-
2005
- 2005-07-22 ZA ZA200505934A patent/ZA200505934B/en unknown
- 2005-07-29 HR HR20050679A patent/HRP20050679A2/en not_active Application Discontinuation
- 2005-07-29 MA MA28417A patent/MA27651A1/en unknown
- 2005-08-29 NO NO20054006A patent/NO20054006L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2850652A1 (en) | 2004-08-06 |
| NZ541270A (en) | 2008-11-28 |
| CN1768054A (en) | 2006-05-03 |
| MA27651A1 (en) | 2005-12-01 |
| TW200505898A (en) | 2005-02-16 |
| MXPA05007407A (en) | 2005-09-12 |
| WO2004070050A2 (en) | 2004-08-19 |
| ATE482207T1 (en) | 2010-10-15 |
| DE602004029236D1 (en) | 2010-11-04 |
| NO20054006D0 (en) | 2005-08-29 |
| MEP22608A (en) | 2010-06-10 |
| RS20050657A (en) | 2007-06-04 |
| CA2513631A1 (en) | 2004-08-19 |
| EP1599464A2 (en) | 2005-11-30 |
| RU2341523C2 (en) | 2008-12-20 |
| BRPI0407091A (en) | 2006-01-24 |
| JP2006517569A (en) | 2006-07-27 |
| NO20054006L (en) | 2005-10-13 |
| EP1599464B1 (en) | 2010-09-22 |
| AR042936A1 (en) | 2005-07-06 |
| ZA200505934B (en) | 2007-06-27 |
| PL377811A1 (en) | 2006-02-20 |
| KR20050098286A (en) | 2005-10-11 |
| FR2850652B1 (en) | 2008-05-30 |
| WO2004070050A3 (en) | 2005-02-17 |
| PE20040808A1 (en) | 2004-12-31 |
| JP4604020B2 (en) | 2010-12-22 |
| RU2005127335A (en) | 2006-09-10 |
| AU2004209319A1 (en) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050679A2 (en) | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors | |
| TW200617004A (en) | Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| NO20082976L (en) | Sulfur-containing cyclic urea derivatives, their preparation and their pharmaceutical use as kinase inhibitors | |
| NO20063780L (en) | Process for the preparation of 2-aminithiazole-5-aromatic carboxamide as kinase inhibitors. | |
| CO5580747A2 (en) | N-ADAMANTILMETILO DERIVATIVES AND INTERMEDIARIES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | |
| NO20063028L (en) | 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors | |
| AR057979A1 (en) | PIRAZOLPIRIMIDINAS AS INHIBITORS OF PROTEIN QUINASA. PHARMACEUTICAL COMPOSITIONS. | |
| HRP20080113T3 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
| AR053405A1 (en) | SUBSTITUTED UREA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOPATIAS | |
| MXPA03010129A (en) | N-aroyl cyclic amines. | |
| AR050181A1 (en) | UREA DERIVATIVES SUBSTITUTED CYCLES, ITS PREPARATION AND PHARMACEUTICAL USE AS QUINASA INHIBITORS | |
| ES2333802T3 (en) | NON-NUCLEIC INHIBITORS OF INVERSE TRANSCRIPT. | |
| NO20080456L (en) | Novel 2,4-dianilinopyrimidine derivatives, their preparation and their use as drugs, pharmaceutical compositions and, in particular, as IKK inhibitors | |
| NO20051826L (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
| NO20082975L (en) | Novel cyclic urea derivatives, their preparation and their pharmaceutical use as kinase inhibitors | |
| DE60142934D1 (en) | PHARMACEUTICAL DOPAMINE-GLYCOCONJUGATE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
| NO20061045L (en) | imidazole | |
| SE0303541D0 (en) | New compounds | |
| AR045909A1 (en) | SOLID FORMULATION CONTAINING A XANTINA DERIVATIVE | |
| NO20062202L (en) | Amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3,4-dihydro-2H-chromene-6-yl derivatives, processes and intermediates for their preparation, and drugs containing these compounds | |
| MXPA04002495A (en) | Imidazopyridine compounds as 5-ht4. | |
| NO20060079L (en) | 6- (1,1-Difluoroalkyl) -4-aminopicolinates and their use as herbicides | |
| AR036812A1 (en) | INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES | |
| TW200745048A (en) | Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors | |
| MXPA05007519A (en) | Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090127 Year of fee payment: 6 |
|
| OBST | Application withdrawn |